Full Generic Medicine Info
Dosage/Direction for Use

Short-term management of anxiety, Insomnia
Adult: 7.5-15 mg daily in the evening.
Elderly: Dose reductions may be necessary.
Severe respiratory insufficiency, myasthenia, angle-closure glaucoma. Children <15 yr. Porphyria.
Special Precautions
May impair ability to drive or operate machinery. Respiratory insufficiency. Renal and hepatic impairment. Myasthenia gravis. Elderly. Do not withdraw abruptly. May cause physical dependence with chronic use. Pregnancy and lactation.
Adverse Reactions
Rash, pruritus, muscular hypotonia, somnolence, ataxia, vertigo, confusion, anterograde amnesia, withdrawal syndrome (prolonged treatment), drowsiness, blurred vision, urinary retention.
Drug Interactions
Additive CNS depression may occur with alcohol, antidepressants, antihistamines, antipsychotics, general anaesthetics, other hypnotics or sedatives, opioid analgesics and cisapride.
Nordazepam is a long-acting benzodiazepine. It enhances the activity of GABA, a major inhibitory neurotransmitter in the brain, by binding to specific sites in the GABA receptors.
Absorption: Absorbed from the GI tract. Peak plasma levels after 2 hr (oral).
Distribution: Protein-binding: 97%.
Metabolism: Converted to oxazepam.
Excretion: Half-life: 50-120 hr.
CIMS Class
ATC Classification
N05BA16 - nordazepam ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Disclaimer: This information is independently developed by CIMS based on nordazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in